Interpace Biosciences Inkomsten in het verleden
Verleden criteriumcontroles 3/6
Interpace Biosciences has been growing earnings at an average annual rate of 50.7%, while the Healthcare industry saw earnings growing at 5.4% annually. Revenues have been growing at an average rate of 9.7% per year.
Belangrijke informatie
50.7%
Groei van de winst
52.7%
Groei van de winst per aandeel
Healthcare Groei van de industrie | 8.5% |
Inkomstengroei | 9.7% |
Rendement op eigen vermogen | n/a |
Nettomarge | 7.2% |
Laatste winstupdate | 30 Jun 2024 |
Recente prestatie-updates uit het verleden
Opbrengsten en kosten
Hoe Interpace Biosciences geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
---|---|---|---|---|
30 Jun 24 | 42 | 3 | 19 | 1 |
31 Mar 24 | 41 | 1 | 20 | 1 |
31 Dec 23 | 40 | 1 | 20 | 1 |
30 Sep 23 | 38 | -1 | 19 | 1 |
30 Jun 23 | 37 | -2 | 20 | 1 |
31 Mar 23 | 34 | -4 | 20 | 1 |
31 Dec 22 | 32 | -6 | 20 | 1 |
30 Sep 22 | 33 | -6 | 21 | 1 |
30 Jun 22 | 32 | -6 | 21 | 1 |
31 Mar 22 | 31 | -4 | 20 | 1 |
31 Dec 21 | 33 | -7 | 20 | 1 |
30 Sep 21 | 34 | -13 | 22 | 2 |
30 Jun 21 | 34 | -18 | 24 | 2 |
31 Mar 21 | 33 | -24 | 25 | 3 |
31 Dec 20 | 32 | -29 | 27 | 3 |
30 Sep 20 | 27 | -32 | 27 | 3 |
30 Jun 20 | 26 | -33 | 28 | 3 |
31 Mar 20 | 27 | -33 | 28 | 3 |
31 Dec 19 | 24 | -27 | 25 | 3 |
30 Sep 19 | 26 | -20 | 23 | 3 |
30 Jun 19 | 24 | -16 | 19 | 2 |
31 Mar 19 | 23 | -12 | 18 | 2 |
31 Dec 18 | 22 | -12 | 17 | 2 |
30 Sep 18 | 20 | -13 | 18 | 2 |
30 Jun 18 | 19 | -13 | 18 | 2 |
31 Mar 18 | 17 | -18 | 17 | 2 |
31 Dec 17 | 16 | -13 | 17 | 1 |
30 Sep 17 | 15 | -1 | 15 | 2 |
30 Jun 17 | 14 | -5 | 15 | 2 |
31 Mar 17 | 14 | -3 | 16 | 2 |
31 Dec 16 | 13 | -8 | 16 | 2 |
30 Sep 16 | 13 | -23 | 19 | 2 |
30 Jun 16 | 12 | -23 | 20 | 2 |
31 Mar 16 | 10 | -28 | 23 | 2 |
31 Dec 15 | 9 | -31 | 25 | 2 |
30 Sep 15 | -83 | -31 | 13 | 2 |
30 Jun 15 | -57 | -27 | 15 | 1 |
31 Mar 15 | -28 | -20 | 15 | 0 |
31 Dec 14 | 1 | -13 | 15 | 0 |
30 Sep 14 | 123 | -6 | 23 | 0 |
30 Jun 14 | 129 | -5 | 23 | 0 |
31 Mar 14 | 135 | -4 | 24 | 0 |
31 Dec 13 | 147 | -2 | 25 | 0 |
Kwaliteitswinsten: IDXG has high quality earnings.
Groeiende winstmarge: IDXG became profitable in the past.
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: IDXG has become profitable over the past 5 years, growing earnings by 50.7% per year.
Versnelling van de groei: IDXG has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Winst versus industrie: IDXG has become profitable in the last year, making it difficult to compare its past year earnings growth to the Healthcare industry (11.4%).
Rendement op eigen vermogen
Hoge ROE: IDXG's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.